Nezih Hekim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nezih Hekim has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Lutfiye Karcioglu Batur
Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University
7 shared publications - Collet Dandara
Division of Human Genetics, Department of Pathology and Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
4 shared publications - Hüseyin Aydın
Department of Medical Biochemistry, Faculty of Medicine, Sivas Cumhuriyet University, Türkiye
4 shared publications - Sami Keleş
Ahenk Medical Diagnostic and Research Laboratory, Istanbul, Turkey
3 shared publications - Yusuf Kenan Tekin
Sivas Cumhuriyet Üniversitesi
3 shared publications - Adrián Llerena
INUBE Biosanitary University Research Institute , University of Extremadura , Badajoz , Spain
2 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Springer Nature in Scientific Reports
Hidden baseline heterogeneity can mask treatment effects in randomized xenograft studies
Randomization and standardized analytical workflows are central to preclinical oncology, yet they do not necessarily ensure biological comparability at baseline. Using a real-world xenograft efficacy dataset generated under standard CRO conditions, we show that biologically meaningful treatment effects can remain statistically undetected when baseline heterogeneity is not explicitly considered. Although treatment groups appeared balanced at study entry by conventional summaries, baseline tumour volume exhibited latent structure within the cohort. Pooled group-level analyses reported no significant treatment effect, whereas baseline-aware evaluation of tumour growth trajectories revealed a responder subpopulation whose signal was masked by aggregation. This discrepancy did not arise from deficiencies in experimental conduct or data quality, but from limitations of pooled inference in the presence of structured baseline variability. Extending this framework to publicly available xenograft datasets, we observed that baseline tumour volume heterogeneity is common under routine preclinical workflows and can similarly alter efficacy interpretation. Together, these findings indicate that baseline tumour burden represents a biologically consequential source of hidden heterogeneity and that baseline-aware analytical strategies can improve the sensitivity and interpretability of preclinical efficacy assessment without deviation from standard experimental practice.
- 7 November 2026
- Published by Springer Nature in Scientific Reports
Open AccessHidden baseline heterogeneity can mask treatment effects in randomized xenograft studies
Randomization and standardized analytical workflows are central to preclinical oncology, yet they do not necessarily ensure biological comparability at baseline. Using a real-world xenograft efficacy dataset generated under standard CRO conditions, we show that biologically meaningful treatment effects can remain statistically undetected when baseline heterogeneity is not explicitly considered. Although treatment groups appeared balanced at study entry by conventional summaries, baseline tumour volume exhibited latent structure within the cohort. Pooled group-level analyses reported no significant treatment effect, whereas baseline-aware evaluation of tumour growth trajectories revealed a responder subpopulation whose signal was masked by aggregation. This discrepancy did not arise from deficiencies in experimental conduct or data quality, but from limitations of pooled inference in the presence of structured baseline variability. Extending this framework to publicly available xenograft datasets, we observed that baseline tumour volume heterogeneity is common under routine preclinical workflows and can similarly alter efficacy interpretation. Together, these findings indicate that baseline tumour burden represents a biologically consequential source of hidden heterogeneity and that baseline-aware analytical strategies can improve the sensitivity and interpretability of preclinical efficacy assessment without deviation from standard experimental practice.
- Open Access
- 1 October 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 30 (6) , 1-8
Anticancer effects of the Kiperin Purple Collagen complex: Evidence from HCT116 and MIA PaCa‑2 cell models
Purple Collagen is a bioactive complex containing double-hydrolyzed collagens (types I, II, III, V and X) and various bioactive components (inulin, elderberry extract, magnesium citrate and malate, eggshell membrane, bromelain, black cumin extract and liposomal vitamin C). These bioactive compounds have attracted increasing scientific interest due to their ability to modulate key cancer-associated pathways, including the inhibition of cell proliferation and migration, suppression of oxidative stress via free radical scavenging and induction of apoptosis through mitochondrial and caspase-dependent mechanisms. While individual components of the Purple Collagen complex (PCC) have been associated with various health benefits, their combined effects on cancer cell behavior remain largely unexplored. The present study investigated the effects of PCC on cell proliferation, migration, oxidative stress and apoptosis in two cancer cell lines: HCT116 (colorectal carcinoma) and MIA PaCa-2 (pancreas carcinoma). The cell viability, migration, oxidative stress [total oxidant status (TOS)/total antioxidant status (TAS)] and apoptotic and cell cycle regulatory markers (BAX, BCL2, TP53 and cyclin-dependent kinase inhibitor 1) were analyzed following treatment with 1 µg/ml PCC. Experiments were performed in vitro, and statistical significance was assessed. Cell counts for viability and proliferation analyses were obtained with a Thoma hemocytometer after trypan blue staining. PCC treatment significantly reduced cell proliferation in HCT116 and MIA PaCa-2 cells (P=0.0141 and P=0.0004, respectively). Migration assays demonstrated significant reductions at intermediate time points in both cell lines, HCT116 (P=0.0091) and MIA PaCa-2 cells (P=0.01). TOS and TAS levels revealed a cell-type-specific response, with a marked TAS decrease in HCT116 (P=0.0095). PCC caused an apoptotic and cell cycle regulatory effect, affecting BCL2 and p21 expression levels significantly in both cell lines (P<0.05). PCC exhibits notable cell-type-specific effects, inhibiting proliferation and migration in colon and pancreas carcinoma cells while modulating oxidative stress and apoptosis. The findings highlight the potential of bioactive compounds as selective modulators of cancer cell behavior. Further in vivo studies are required to evaluate these effects and their clinical relevance.
- 1 October 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 30 (6) , 1-8
Open AccessAnticancer effects of the Kiperin Purple Collagen complex: Evidence from HCT116 and MIA PaCa‑2 cell models
Purple Collagen is a bioactive complex containing double-hydrolyzed collagens (types I, II, III, V and X) and various bioactive components (inulin, elderberry extract, magnesium citrate and malate, eggshell membrane, bromelain, black cumin extract and liposomal vitamin C). These bioactive compounds have attracted increasing scientific interest due to their ability to modulate key cancer-associated pathways, including the inhibition of cell proliferation and migration, suppression of oxidative stress via free radical scavenging and induction of apoptosis through mitochondrial and caspase-dependent mechanisms. While individual components of the Purple Collagen complex (PCC) have been associated with various health benefits, their combined effects on cancer cell behavior remain largely unexplored. The present study investigated the effects of PCC on cell proliferation, migration, oxidative stress and apoptosis in two cancer cell lines: HCT116 (colorectal carcinoma) and MIA PaCa-2 (pancreas carcinoma). The cell viability, migration, oxidative stress [total oxidant status (TOS)/total antioxidant status (TAS)] and apoptotic and cell cycle regulatory markers (BAX, BCL2, TP53 and cyclin-dependent kinase inhibitor 1) were analyzed following treatment with 1 µg/ml PCC. Experiments were performed in vitro, and statistical significance was assessed. Cell counts for viability and proliferation analyses were obtained with a Thoma hemocytometer after trypan blue staining. PCC treatment significantly reduced cell proliferation in HCT116 and MIA PaCa-2 cells (P=0.0141 and P=0.0004, respectively). Migration assays demonstrated significant reductions at intermediate time points in both cell lines, HCT116 (P=0.0091) and MIA PaCa-2 cells (P=0.01). TOS and TAS levels revealed a cell-type-specific response, with a marked TAS decrease in HCT116 (P=0.0095). PCC caused an apoptotic and cell cycle regulatory effect, affecting BCL2 and p21 expression levels significantly in both cell lines (P<0.05). PCC exhibits notable cell-type-specific effects, inhibiting proliferation and migration in colon and pancreas carcinoma cells while modulating oxidative stress and apoptosis. The findings highlight the potential of bioactive compounds as selective modulators of cancer cell behavior. Further in vivo studies are required to evaluate these effects and their clinical relevance.
- Open Access
- 15 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (5) , 364
Kiperin Double-Hydrolyzed Collagen as a Potential Anti-Tumor Agent: Effects on HCT116 Colon Carcinoma Cells and Oxidative Stress Modulation
Double-hydrolyzed collagen, a key structural protein, has gained increasing attention for its role in cancer progression and its potential therapeutic applications. This study aims to investigate the effects of double-hydrolyzed collagen (Type I and III peptides) on HCT116 colon carcinoma cells and CCD-18Co fibroblasts as a normal control. Cells were treated with 0.5 µg/mL, 1 µg/mL, and 1.5 µg/mL of collagen peptide solution. HCT116 and CCD-18Co cells were cultured under standard conditions and treated with 1 µg/mL collagen. Cell viability (MTT assay), migration (scratch assay), oxidative stress (TAS/TOS kits), TNF-α expression (qRT-PCR), and tumor marker levels (CA19-9, CEA, CA72-4, and CYFRA 21-1; CLIA) were evaluated. Cell viability, proliferation, migration, oxidative stress, and tumor marker levels were assessed. Statistical analyses were performed to determine significance. Double-hydrolyzed collagen treatment significantly increased CCD-18Co fibroblast proliferation (p = 0.0143), while HCT116 cancer cell numbers significantly decreased (p = 0.0045). Migration of HCT116 cells was markedly reduced (p < 0.0001), whereas no significant effect was observed in CCD-18Co fibroblasts (p = 0.559). Oxidative stress analysis showed decreased total oxidative status (TOS) and increased total antioxidant status (TAS) in HCT116 cells (p = 0.0075 and p = 0.0095, respectively), with no significant changes in normal fibroblasts. Among tumor markers, CA19-9 levels were significantly reduced in HCT116 cells (p = 0.013), while CEA, CA72-4, and CYFRA 21-1 remained unchanged. TNF-α gene expression analysis confirmed the absence of inflammatory or adverse effects in normal fibroblasts. These findings suggest that double-hydrolyzed collagen selectively inhibits colon cancer cell proliferation and migration, modulates oxidative stress, and reduces CA19-9 levels while promoting fibroblast growth. The differential effects between cancerous and normal cells highlight collagen’s potential as a complementary therapeutic approach for colorectal cancer. Further research is needed to elucidate the underlying mechanisms and assess its clinical applicability. Double-hydrolyzed collagen appears to be a safe and beneficial dietary component with promising biological effects and therapeutic potential.
- 15 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (5) , 364
Open AccessKiperin Double-Hydrolyzed Collagen as a Potential Anti-Tumor Agent: Effects on HCT116 Colon Carcinoma Cells and Oxidative Stress Modulation
Double-hydrolyzed collagen, a key structural protein, has gained increasing attention for its role in cancer progression and its potential therapeutic applications. This study aims to investigate the effects of double-hydrolyzed collagen (Type I and III peptides) on HCT116 colon carcinoma cells and CCD-18Co fibroblasts as a normal control. Cells were treated with 0.5 µg/mL, 1 µg/mL, and 1.5 µg/mL of collagen peptide solution. HCT116 and CCD-18Co cells were cultured under standard conditions and treated with 1 µg/mL collagen. Cell viability (MTT assay), migration (scratch assay), oxidative stress (TAS/TOS kits), TNF-α expression (qRT-PCR), and tumor marker levels (CA19-9, CEA, CA72-4, and CYFRA 21-1; CLIA) were evaluated. Cell viability, proliferation, migration, oxidative stress, and tumor marker levels were assessed. Statistical analyses were performed to determine significance. Double-hydrolyzed collagen treatment significantly increased CCD-18Co fibroblast proliferation (p = 0.0143), while HCT116 cancer cell numbers significantly decreased (p = 0.0045). Migration of HCT116 cells was markedly reduced (p < 0.0001), whereas no significant effect was observed in CCD-18Co fibroblasts (p = 0.559). Oxidative stress analysis showed decreased total oxidative status (TOS) and increased total antioxidant status (TAS) in HCT116 cells (p = 0.0075 and p = 0.0095, respectively), with no significant changes in normal fibroblasts. Among tumor markers, CA19-9 levels were significantly reduced in HCT116 cells (p = 0.013), while CEA, CA72-4, and CYFRA 21-1 remained unchanged. TNF-α gene expression analysis confirmed the absence of inflammatory or adverse effects in normal fibroblasts. These findings suggest that double-hydrolyzed collagen selectively inhibits colon cancer cell proliferation and migration, modulates oxidative stress, and reduces CA19-9 levels while promoting fibroblast growth. The differential effects between cancerous and normal cells highlight collagen’s potential as a complementary therapeutic approach for colorectal cancer. Further research is needed to elucidate the underlying mechanisms and assess its clinical applicability. Double-hydrolyzed collagen appears to be a safe and beneficial dietary component with promising biological effects and therapeutic potential.
- 27 March 2025
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 17 (1) , 84-90
Biomarkers of Vitamin D Sufficiency: Vitamin D metabolite levels do not depend on 25-Hydroxyvitamin D2 levels in healthy Turkish individuals
Objective: Patient-specific factors may influence the dose of supplemental vitamin D necessary for adequacy, and it is important to verify which metabolite is considered clinically meaningful in order to prescribe vitamin D supplements. We assessed the relationship between 25(OH)D2 and free vitamin D levels in healthy Turkish population and those with vitamin D deficiency. Methods: Blood samples were taken from 92 healthy adults over the age of 18, representing both genders (n = 38 males and n = 54 females). Total 25(OH)D concentrations were determined using an immunoassay method called CMIA. In addition, 25(OH)D3 and vitamin D2 levels in serum were measured using liquid chromatography-mass spectrometry (LC-MS). Free 25(OH)D was measured and calculated according to the Bikle method. Results: Among the participants, 54% exhibited total 25(OH)D3 levels below 20 ng/mL. Those with total 25(OH)D3 concentrations of 20 ng/mL or higher had significantly elevated mean serum levels of 25(OH)D3 and free vitamin D compared to those with levels below 20 ng/mL (P < 0.001). In opposition, the mean concentration of 25(OH)D2 did not show significant variation based on the criteria for vitamin D sufficiency. Additionally, serum levels of 25(OH)D2 were consistent across individuals, regardless of their free vitamin D concentrations. Conclusion: The mean concentrations of serum 25(OH)D3 measured by LC-MS and free vitamin D affects the total 25(OH)D3 concentration as calculated by an automated system and indicates vitamin D deficiency. The mean concentration of 25(OH)D2 in serum, however, didn't differ among individuals according to vitamin D deficiency criteria and concentration of free vitamin D, thus does not directly indicate vitamin D deficiency.
- 27 March 2025
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 17 (1) , 84-90
Biomarkers of Vitamin D Sufficiency: Vitamin D metabolite levels do not depend on 25-Hydroxyvitamin D2 levels in healthy Turkish individuals
Objective: Patient-specific factors may influence the dose of supplemental vitamin D necessary for adequacy, and it is important to verify which metabolite is considered clinically meaningful in order to prescribe vitamin D supplements. We assessed the relationship between 25(OH)D2 and free vitamin D levels in healthy Turkish population and those with vitamin D deficiency. Methods: Blood samples were taken from 92 healthy adults over the age of 18, representing both genders (n = 38 males and n = 54 females). Total 25(OH)D concentrations were determined using an immunoassay method called CMIA. In addition, 25(OH)D3 and vitamin D2 levels in serum were measured using liquid chromatography-mass spectrometry (LC-MS). Free 25(OH)D was measured and calculated according to the Bikle method. Results: Among the participants, 54% exhibited total 25(OH)D3 levels below 20 ng/mL. Those with total 25(OH)D3 concentrations of 20 ng/mL or higher had significantly elevated mean serum levels of 25(OH)D3 and free vitamin D compared to those with levels below 20 ng/mL (P < 0.001). In opposition, the mean concentration of 25(OH)D2 did not show significant variation based on the criteria for vitamin D sufficiency. Additionally, serum levels of 25(OH)D2 were consistent across individuals, regardless of their free vitamin D concentrations. Conclusion: The mean concentrations of serum 25(OH)D3 measured by LC-MS and free vitamin D affects the total 25(OH)D3 concentration as calculated by an automated system and indicates vitamin D deficiency. The mean concentration of 25(OH)D2 in serum, however, didn't differ among individuals according to vitamin D deficiency criteria and concentration of free vitamin D, thus does not directly indicate vitamin D deficiency.
- Open Access
- 3 September 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (17) , 1941
Investigation of the Relationship between Vitamin D Deficiency and Vitamin D-Binding Protein Polymorphisms in Severe COVID-19 Patients
This study explores the association of vitamin D-binding protein (VDBP) gene polymorphisms, vitamin D levels, and the severity of COVID-19, including the need for intensive care unit (ICU) hospitalization. We analyzed a cohort of 56 consecutive age- and gender-matched adult COVID-19-positive patients and categorized them into three groups: outpatients with mild illness, inpatients with moderate disease, and ICU patients. We measured levels of free, total, and bioavailable 25-hydroxyvitamin D [25(OH)D], VDBP, and albumin. VDBP polymorphisms rs5488 and rs7041 were identified using real-time PCR. A significant proportion of ICU patients were vitamin D-deficient (56.25%) compared to outpatients (10%) and inpatients (5%) (p = 0.0003). ICU patients also had notably lower levels of VDBP (median: 222 mg/L) and total 25(OH)D (median: 18.8 ng/mL). Most patients carried heterozygous rs7041 (60.7%) and wild-type rs4588 (58.9%) genotypes. The distribution of rs7041 SNP varied significantly among groups (p = 0.0301), while rs4588 SNP distribution did not (p = 0.424). Heterozygous rs4588 patients had significantly lower VDBP levels (p = 0.029) and reduced bioavailable 25(OH)D compared to those with wild-type rs4588 (p = 0.020). Our findings indicate that VDBP gene polymorphisms, particularly rs7041 and rs4588, are associated with vitamin D status and the severity of COVID-19. The lower VDBP levels and bioavailable vitamin D in ICU patients suggest that these genetic variants may influence disease severity and hospitalization needs. These results highlight the potential role of VDBP polymorphisms in COVID-19 severity, suggesting that genetic screening could be valuable in assessing the risk of severe outcomes and guiding personalized treatment strategies.
- 3 September 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (17) , 1941
Open AccessInvestigation of the Relationship between Vitamin D Deficiency and Vitamin D-Binding Protein Polymorphisms in Severe COVID-19 Patients
This study explores the association of vitamin D-binding protein (VDBP) gene polymorphisms, vitamin D levels, and the severity of COVID-19, including the need for intensive care unit (ICU) hospitalization. We analyzed a cohort of 56 consecutive age- and gender-matched adult COVID-19-positive patients and categorized them into three groups: outpatients with mild illness, inpatients with moderate disease, and ICU patients. We measured levels of free, total, and bioavailable 25-hydroxyvitamin D [25(OH)D], VDBP, and albumin. VDBP polymorphisms rs5488 and rs7041 were identified using real-time PCR. A significant proportion of ICU patients were vitamin D-deficient (56.25%) compared to outpatients (10%) and inpatients (5%) (p = 0.0003). ICU patients also had notably lower levels of VDBP (median: 222 mg/L) and total 25(OH)D (median: 18.8 ng/mL). Most patients carried heterozygous rs7041 (60.7%) and wild-type rs4588 (58.9%) genotypes. The distribution of rs7041 SNP varied significantly among groups (p = 0.0301), while rs4588 SNP distribution did not (p = 0.424). Heterozygous rs4588 patients had significantly lower VDBP levels (p = 0.029) and reduced bioavailable 25(OH)D compared to those with wild-type rs4588 (p = 0.020). Our findings indicate that VDBP gene polymorphisms, particularly rs7041 and rs4588, are associated with vitamin D status and the severity of COVID-19. The lower VDBP levels and bioavailable vitamin D in ICU patients suggest that these genetic variants may influence disease severity and hospitalization needs. These results highlight the potential role of VDBP polymorphisms in COVID-19 severity, suggesting that genetic screening could be valuable in assessing the risk of severe outcomes and guiding personalized treatment strategies.
- 7 September 2023
- Published by Galenos Yayinevi in Eurasian Journal of Emergency Medicine
- Vol. 22 (3) , 203-208
Urea Cycle and Arginine Metabolic Changes in COVID-19 Patients
- 7 September 2023
- Published by Galenos Yayinevi in Eurasian Journal of Emergency Medicine
- Vol. 22 (3) , 203-208
Urea Cycle and Arginine Metabolic Changes in COVID-19 Patients
- Open Access
- 5 January 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (3) , 2471-2478
Association between iron metabolism and SARS-COV-2 infection, determined by ferritin, hephaestin and hypoxia-induced factor-1 alpha levels in COVID-19 patients
Background Due to the growing evidence of the importance of iron status in immune responses, the biomarkers of iron metabolism are of interest in novel Coronavirus Disease 2019 (COVID-19). The present prospective study was carried out to compare iron status indicated by levels of ferritin with the levels of two novel biomarkers related to iron homeostasis, hephaestin and hypoxia-inducible factors-1 (HIF-1α) in the serum of patients with COVID-19 in comparison with a control group. Methods and results Blood samples from 34 COVID-19 patients and from 43 healthy volunteers were collected and the levels of HEPH and HIF-1α were measured by ELISA and compared with levels of serum ferritin. COVID-19 patients had higher serum levels of ferritin than those levels in control group (P < 0.0001). Conversely levels of HIF-1α and HEPH in the COVID-19 group were significantly lower than those of control group (P < 0.0001 for both). An inverse correlation between hephaestin and ferritin as well as between HIF-1α and ferritin was found among all subjects (P < 0.0001), and among COVID-19 patients, but not to statistical significance. Conclusion Levels of hephaestin and HIF-1α were found to be inversely related levels of ferritin across all participants in the study, and to our knowledge this is the first report of hephaestin and HIF-1α as potential markers of iron status. Further studies are needed to corroborate the findings, utilizing a broader range of markers to monitor inflammatory as well as iron status.
- 5 January 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (3) , 2471-2478
Open AccessAssociation between iron metabolism and SARS-COV-2 infection, determined by ferritin, hephaestin and hypoxia-induced factor-1 alpha levels in COVID-19 patients
Background Due to the growing evidence of the importance of iron status in immune responses, the biomarkers of iron metabolism are of interest in novel Coronavirus Disease 2019 (COVID-19). The present prospective study was carried out to compare iron status indicated by levels of ferritin with the levels of two novel biomarkers related to iron homeostasis, hephaestin and hypoxia-inducible factors-1 (HIF-1α) in the serum of patients with COVID-19 in comparison with a control group. Methods and results Blood samples from 34 COVID-19 patients and from 43 healthy volunteers were collected and the levels of HEPH and HIF-1α were measured by ELISA and compared with levels of serum ferritin. COVID-19 patients had higher serum levels of ferritin than those levels in control group (P < 0.0001). Conversely levels of HIF-1α and HEPH in the COVID-19 group were significantly lower than those of control group (P < 0.0001 for both). An inverse correlation between hephaestin and ferritin as well as between HIF-1α and ferritin was found among all subjects (P < 0.0001), and among COVID-19 patients, but not to statistical significance. Conclusion Levels of hephaestin and HIF-1α were found to be inversely related levels of ferritin across all participants in the study, and to our knowledge this is the first report of hephaestin and HIF-1α as potential markers of iron status. Further studies are needed to corroborate the findings, utilizing a broader range of markers to monitor inflammatory as well as iron status.
- 8 April 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 38 (1) , 83-93
Glutamine-Driven Metabolic Adaptation to COVID-19 Infection
Background COVID-19 is known to be transmitted by direct contact, droplets or feces/orally. There are many factors which determines the clinical progression of the disease. Aminoacid disturbance in viral disease is shown in many studies. İn this study we aimed to evaluate the change of aminoacid metabolism especially the aspartate, glutamine and glycine levels which have been associated with an immune defence effect in viral disease. Methods Blood samples from 35 volunteer patients with COVID-19, concretized diagnosis was made by oropharyngeal from nazofaringeal swab specimens and reverse transcriptase-polymerase chain reaction, and 35 control group were analyzed. The amino acid levels were measured with liquid chromatography‐mass spectrometry technology. Two groups were compared by Kolmogorov–Smirnov analysis, Kruskal–Wallis and the Mann–Whitney U. The square test was used to evaluate the tests obtained by counting, and the error level was taken as 0.05. Results The average age of the patient and control group were 48.5 ± 14.9 and 48.8 ± 14.6 years respectively. The decrease in aspartate (p = 5.5 × 10−9) and glutamine levels (p = 9.0 × 10−17) were significiantly in COVID group, whereas Glycine (p = 0.243) increase was not significiant. Conclusions Metabolic pathways, are affected in rapidly dividing cells in viral diseases which are important for immun defence. We determined that aspartate, glutamine and glycine levels in Covid 19 patients were affected by the warburg effect, malate aspartate shuttle, glutaminolysis and pentose phosphate pathway. Enteral or parenteral administration of these plasma amino acid levels will correct the duration and pathophysiology of the patients' stay in hospital and intensive care.
- 8 April 2022
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 38 (1) , 83-93
Glutamine-Driven Metabolic Adaptation to COVID-19 Infection
Background COVID-19 is known to be transmitted by direct contact, droplets or feces/orally. There are many factors which determines the clinical progression of the disease. Aminoacid disturbance in viral disease is shown in many studies. İn this study we aimed to evaluate the change of aminoacid metabolism especially the aspartate, glutamine and glycine levels which have been associated with an immune defence effect in viral disease. Methods Blood samples from 35 volunteer patients with COVID-19, concretized diagnosis was made by oropharyngeal from nazofaringeal swab specimens and reverse transcriptase-polymerase chain reaction, and 35 control group were analyzed. The amino acid levels were measured with liquid chromatography‐mass spectrometry technology. Two groups were compared by Kolmogorov–Smirnov analysis, Kruskal–Wallis and the Mann–Whitney U. The square test was used to evaluate the tests obtained by counting, and the error level was taken as 0.05. Results The average age of the patient and control group were 48.5 ± 14.9 and 48.8 ± 14.6 years respectively. The decrease in aspartate (p = 5.5 × 10−9) and glutamine levels (p = 9.0 × 10−17) were significiantly in COVID group, whereas Glycine (p = 0.243) increase was not significiant. Conclusions Metabolic pathways, are affected in rapidly dividing cells in viral diseases which are important for immun defence. We determined that aspartate, glutamine and glycine levels in Covid 19 patients were affected by the warburg effect, malate aspartate shuttle, glutaminolysis and pentose phosphate pathway. Enteral or parenteral administration of these plasma amino acid levels will correct the duration and pathophysiology of the patients' stay in hospital and intensive care.
- Open Access
- 12 October 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (10) , 696
Vitamin-D Binding Protein Gene Polymorphisms and Serum 25-Hydroxyvitamin-D in a Turkish Population
The rs7041 and rs4588 polymorphisms found in the GC gene, encoding vitamin D-binding protein (DBP), have distinct biochemical phenotypes. The aim of this study was to investigate vitamin D parameters with these polymorphisms, in individuals with possible vitamin D deficiency. The most common (49% of the cohort) genotype in rs7041 was GT, especially among individuals with high levels of free 25(OH)D calculated but with low levels of bioavailable 25(OH)D, and in rs4588 it was AC in particular among the individuals with low levels of bioavailable 25(OH)D. The most common phenotypes were Gc1s/2 (35.3%) and Gc1s/1s (31.4%), and Gc1f/1f was rare (5.9%). The variations in free and bioavailable 25(OH)D levels among healthy Turkish individuals may be attributed to the variations in total 25(OH)D as well as GC gene polymorphisms. The Turkish population shares a similarity for allele frequencies of rs7041 with the European population and similarity for allele frequencies of rs4588 with Gujarati Indians, and this may also be important in relation to certain ethnic populations showing associations between vitamin D and COVID-19.
- 12 October 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (10) , 696
Open AccessVitamin-D Binding Protein Gene Polymorphisms and Serum 25-Hydroxyvitamin-D in a Turkish Population
The rs7041 and rs4588 polymorphisms found in the GC gene, encoding vitamin D-binding protein (DBP), have distinct biochemical phenotypes. The aim of this study was to investigate vitamin D parameters with these polymorphisms, in individuals with possible vitamin D deficiency. The most common (49% of the cohort) genotype in rs7041 was GT, especially among individuals with high levels of free 25(OH)D calculated but with low levels of bioavailable 25(OH)D, and in rs4588 it was AC in particular among the individuals with low levels of bioavailable 25(OH)D. The most common phenotypes were Gc1s/2 (35.3%) and Gc1s/1s (31.4%), and Gc1f/1f was rare (5.9%). The variations in free and bioavailable 25(OH)D levels among healthy Turkish individuals may be attributed to the variations in total 25(OH)D as well as GC gene polymorphisms. The Turkish population shares a similarity for allele frequencies of rs7041 with the European population and similarity for allele frequencies of rs4588 with Gujarati Indians, and this may also be important in relation to certain ethnic populations showing associations between vitamin D and COVID-19.
- Open Access
- 23 September 2020
- Published by Springer Nature in Research Square
Correlations of IL-6, IL-6R, IL-10 and IL-17 gene polymorphisms with the prevalence of COVID-2019 infection and its mortality rate
The pathogenesis of COVID-19 implicates a potent inflammatory response resulting in cytokine storm. We aimed to evaluate association between polymorphisms in IL-6 gene at rs1800796/rs1800795, IL-6R at rs2228145, IL-10 at rs1800896 and rs1800871, IL-17 at rs2275913 and rs76378, and the prevalence (per million) and mortality rates (per million) of COVID-19 among populations of China, Japan, India, Iran, Spain, Italy, Mexico, Netherlands, Sweden, Turkey, Finland, Brazil, Czechia, Russia, Poland. AG and GG genotypes of rs2275913 in IL-17A was found to be correlated with prevalence and mortality rates, especially in Spain and Brazil populations (pIL-17F was not dependent on the high frequencies in all populations. However, the polymorphisms in IL-6, IL-6R and IL-10 appear not to be correlated with prevalence and mortality rates. The variations in the prevalence of COVID-19 and its mortality rates among countries may be explained by cytokine storm differed by the polymorphisms of rs2275913 locus in IL-17A gene. However, the prevalence of infection differs from severity of COVID-19, based on many factors such as public awareness, behaviors and antiviral policy of countries. Yet, the severity of disease induced by viral infection might be associated with genetic host factors including immune profiling.
- 23 September 2020
- Published by Springer Nature in Research Square
Open AccessCorrelations of IL-6, IL-6R, IL-10 and IL-17 gene polymorphisms with the prevalence of COVID-2019 infection and its mortality rate
The pathogenesis of COVID-19 implicates a potent inflammatory response resulting in cytokine storm. We aimed to evaluate association between polymorphisms in IL-6 gene at rs1800796/rs1800795, IL-6R at rs2228145, IL-10 at rs1800896 and rs1800871, IL-17 at rs2275913 and rs76378, and the prevalence (per million) and mortality rates (per million) of COVID-19 among populations of China, Japan, India, Iran, Spain, Italy, Mexico, Netherlands, Sweden, Turkey, Finland, Brazil, Czechia, Russia, Poland. AG and GG genotypes of rs2275913 in IL-17A was found to be correlated with prevalence and mortality rates, especially in Spain and Brazil populations (pIL-17F was not dependent on the high frequencies in all populations. However, the polymorphisms in IL-6, IL-6R and IL-10 appear not to be correlated with prevalence and mortality rates. The variations in the prevalence of COVID-19 and its mortality rates among countries may be explained by cytokine storm differed by the polymorphisms of rs2275913 locus in IL-17A gene. However, the prevalence of infection differs from severity of COVID-19, based on many factors such as public awareness, behaviors and antiviral policy of countries. Yet, the severity of disease induced by viral infection might be associated with genetic host factors including immune profiling.